Toward a chemotherapy and allo-HSCT free future: the evolution of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia
Philadelphia-positive leukemia treatment is gradually moving away from harsh chemotherapy toward targeted drugs and cellular therapies with fewer side effects.
This review traces the evolution of Ph+ ALL management from imatinib through 2nd/3rd-generation TKIs to chemotherapy-free combinations with blinatumomab and CAR-T cells, with increasing evidence supporting MRD-guided decisions on allo-HSCT necessity. Future progress involves asciminib, venetoclax, and genomic precision medicine integration.
What the study was
- Study design
- Narrative review
- Population
- Ph+ ALL patients across treatment eras
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Frontiers in Immunology
Why it surfaced
Single-author review summarizing Ph+ ALL landscape; highly relevant to hematologic malignancies and CAR-T watchlist topics; score of 7 (solid STANDARD, design limited by review format).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.